BRAF and neoplasm: Interestingly, we observed that BAY 87-2243 displayed increased anti-tumor efficacy compared to single agent treatment when combined with the small molecule mutant BRAF inhibitor vemurafenib in nude mice bearing BRAF mutant melanoma xenografts.